Secukinumab 150 milligram [cosentyx] (DrugBank: Secukinumab)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 271 | Ankylosing spondylitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03639740 (ClinicalTrials.gov) | January 15, 2019 | 17/8/2018 | Treat-to-target With Secukinumab in Axial Spondyloarthritis | TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) | Axial Spondyloarthritis;Ankylosing Spondylitis | Drug: Secukinumab 150 milligram [Cosentyx] | Professor Mikkel Østergaard | Novartis Healthcare A/S | Recruiting | 18 Years | 70 Years | All | 88 | Phase 4 | Denmark |